Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice

3-(3-Morpholinopropyl)-7,8-dihydro-6H-indeno[5,6-e][1,2,4]triazine 1,4-dioxide (SN30- 000), an analog of the well-studied bioreductive prodrug tirapazamine (TPZ), has improved activity against hypoxic cells in tumor xenografts. However, little is known about its biotransformation in normal tissues....

Full description

Bibliographic Details
Main Authors: Yongchuan Gu, Tony T.-A. Chang, Jingli Wang, Jagdish K. Jaiswal, David Edwards, Noel J. Downes, H. D. Sarath Liyanage, Courtney R. H. Lynch, Frederik B. Pruijn, Anthony J. R. Hickey, Michael P. Hay, William R. Wilson, Kevin O. Hicks
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-08-01
Series:Frontiers in Pharmacology
Subjects:
bioreductive prodrugs
tumor hypoxia
benzotriazine N-oxides
SN30000
tirapazamine
reductive metabolism
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2017.00531/full

Internet

http://journal.frontiersin.org/article/10.3389/fphar.2017.00531/full

Similar Items